Onglyza (saxagliptin) is a DPP-4 inhibitor developed by Astrazeneca and approved by the U.S. Food and Drug Administration in 2009.

While hailed as an effective drug-class to combat type 2 diabetes, the FDA has discovered that many DPP-4 inhibitors, including Onglyza, can often heighten the risk of consumers getting a heart attack. This discovery has been validated by multiple medical studies that have discovered three previously undisclosed health risks.

Safety Communication Onglyza Medical Data
Risk of Pancreatic Cancer – 2013 JAMA Internal Medicine – 2013
Risk of Joint Paint – 2015 NCBI – 2012
Risk of Heart Failure – 2016 NMCD – 2014


Is Heart Attack A Side Effect Of Onglyza?

As can be seen from the table above, several dangerous side effects that were previously undisclosed have been discovered in recent years.

Of these discovered side effects, the existence of a heightened heart attack risk has come as the most disturbing.

While AstraZeneca may dispute the connection between their drug and heart attack, several studies published before and after an FDA safety communication in 2013 provide substantial evidence that the claim of a connection is valid.

In addition to confirming studies, the FDA has fielded multiple reports from users alleging heart attacks as a result of taking Onglyza.

As time passes, it is expected that additional studies will once again confirm that there is a connection between Onglyza use and heart attacks.

Additionally, an increase in consumer reports of heart attack development will offer even more confirmation to the already strong claim.

How Dangerous Is Onglyza Related To Heart Attacks?

The most troubling aspect of the heart attack-Onglyza discovery is the deadly nature of heart attacks.

DPP-4 inhibitors are relatively new as they were first brought to market in 2006. With information relating to their connection to heart attacks still being discovered, the full extent of the connection may not be known for years.

Has Onglyza Been Recalled By The U.S. Food and Drug Administration?

As of April 26, 2017, the FDA has yet to issue a recall and it appears unlikely AstraZeneca will self-enforce a recall of this dangerous drug.

Victims are still eligible to file lawsuits against AstraZeneca, though, and should do so if they were victims.

Our Onglyza Lawyers Can Help

Our dangerous prescription drug lawyers can help if you or a loved one has been harmed after taking Onglyza. Lawsuits are being investigated for serious complications that have caused pain and suffering in many patients. You may be entitled to a settlement.

We do not charge any legal fees unless we win your case, and we will pay for all case costs and litigation expenses. If your claim in not successful for any reason, you will owe us nothing. We put that all in writing for you. We’ll help you file you’re lawsuit.

Our No Fee Promise on Onglyza Cases

You can afford to have our great team of Onglyza lawyers on your side. If you choose us, it literally costs you nothing to get started. We promise you in writing:

  • No money to get started
  • We pay all case costs and expenses
  • No legal fees whatsoever unless you receive a settlement
  • Phone calls are always free

Start Your Onglyza Lawsuit Claim

Our dangerous drug lawsuit lawyers will help you file your lawsuit. To get started, you can:

  1. Submit the Free Case Review Box on this page, or
  2. Call 866-280-3417 any time of day to tell us about your case.

We will listen to your story and answer your questions. If you have claim, we will start immediately.

WARNING: There are strict time deadlines for filing Onglyza lawsuit claims.